|Biological Activity or Inhibitors:||1. Cisplatin can enhance the cell-killing effect of radiation, an effect whose intensity varies with the schedule of administration.
2. The antitumor activity of the combination of 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carhonyloxycamptothecin and CDDP(CPT-11) and cisplatin is superior to that of CPT-11 or cisplatin alone.
3. Cisplatin can induce acute kidney injury and neurotoxicity in rats.
|Solvent:||Chloroform, Dichloromethane, Ethyl Acetate, DMSO, Acetone, etc.|
|Storage:||Providing storage is as stated on the product vial and the vial is kept tightly sealed, the product can be stored for up to 24 months(2-8C).
Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20C. Generally, these will be useable for up to two weeks. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.
Need more advice on solubility, usage and handling? Please email to: firstname.lastname@example.org
|After receiving:||The packaging of the product may have turned upside down during transportation, resulting in the natural compounds adhering to the neck or cap of the vial. take the vial out of its packaging and gently shake to let the compounds fall to the bottom of the vial. for liquid products, centrifuge at 200-500 RPM to gather the liquid at the bottom of the vial. try to avoid loss or contamination during handling.|
|1 mg||5 mg||10 mg||20 mg||25 mg|
|1 mM||3.3328 mL||16.6639 mL||33.3278 mL||66.6556 mL||83.3194 mL|
|5 mM||0.6666 mL||3.3328 mL||6.6656 mL||13.3311 mL||16.6639 mL|
|10 mM||0.3333 mL||1.6664 mL||3.3328 mL||6.6656 mL||8.3319 mL|
|50 mM||0.0667 mL||0.3333 mL||0.6666 mL||1.3331 mL||1.6664 mL|
|100 mM||0.0333 mL||0.1666 mL||0.3333 mL||0.6666 mL||0.8332 mL|
N Engl J Med. 1992 Feb 20;326(8):524-30.
|Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer.[Pubmed: 1310160 ]|
|Cisplatin (cis-diamminedichloroplatinum) has been reported to enhance the cell-killing effect of radiation, an effect whose intensity varies with the schedule of administration. We randomly assigned 331 patients with nonmetastatic inoperable non-small-cell lung cancer to one of three treatments: radiotherapy for two weeks (3 Gy given 10 times, in five fractions a week), followed by a three-week rest period and then radiotherapy for two more weeks (2.5 Gy given 10 times, five fractions a week); radiotherapy on the same schedule, combined with 30 mg of Cisplatin per square meter of body-surface area, given on the first day of each treatment week; or radiotherapy on the same schedule, combined with 6 mg of Cisplatin per square meter, given daily before radiotherapy.Cisplatin, given daily in combination with the radiotherapy described here to patients with nonmetastatic but inoperable non-small-cell lung cancer, improved rates of survival and control of local disease at the price of substantial side effects.|
Jpn J Cancer Res. 1993 Feb;84(2):203-7.
|Enhanced antitumor efficacy of a combination of CPT-11, a new derivative of camptothecin, and cisplatin against human lung tumor xenografts.[Pubmed: 8385085]|
|The objective of this study was to evaluate the antitumor efficacy of combined use of 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) and Cisplatin (CDDP). The antitumor activities of CPT-11, CDDP and their combination against 3 human lung tumor xenografts were estimated using congenitally athymic BALB/c (nu/nu) mice. The doses were 47 mg/kg for CPT-11 and 6 mg/kg for CDDP on days 1, 5 and 9. In combination therapy, half of the single dosage of each agent was used. The doses were administered intraperitoneally. The antitumor activity and toxicity were evaluated in terms of the tumor volume and body weight change of mice, respectively. The combination therapy resulted in a statistically significant tumor regression compared to the use of only CPT-11 or CDDP in two tumor xenografts out of three. The toxicity of the combination therapy was no higher than that of CPT-11 or CDDP alone. These results suggest that the antitumor activity of the combination of CPT-11 and CDDP is superior to that of CPT-11 or CDDP alone.|
Food Chem Toxicol. 2012 May;50(5):1675-9.
|Regulation of renal organic anion and cation transporters by thymoquinone in cisplatin induced kidney injury.[Pubmed: 22414646]|
|In previous studies, we have demonstrated the biological activity of thymoquinone (TQ), an active compound extracted from the Nigella sativa plant, against Cisplatin-induced neurotoxicity. Recenty, it was observed that there is an inherent lack in regulation of renal organic anion and cation transporters in Cisplatin-induced nephrotoxicity. Conversely, TQ treatment increased levels of OCT1, OCT2, OAT1 and OAT3 and decreased levels of 8-isoprostane and MDA levels in Cisplatin-treated rats. In conclusion, the present study shows that the TQ synergizes with its nephroprotective effect against Cisplatin-induced acute kidney injury in rats.|